Novo Nordisk Boosts U.S. Obesity Market Strategy Amid Competitor Pressure
Novo Nordisk appoints Poul Weihrauch to its board to bolster its U.S. obesity market position as it faces fierce competition and market challenges. The FDA approved a gene therapy for a rare disease, showcasing ongoing medical innovation.
· 70d ago
